GSE149049 FLT3 inhibition 1 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE149049_FLT3 inhibition_1_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE149049_FLT3 inhibition_1_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE149049_FLT3 inhibition_1_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE149049_FLT3 inhibition_1_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 2910

Gene

long intergenic non-protein coding RNA 2035

Gene

TRG antisense RNA 1

Gene

ITGB2 antisense RNA 1

Gene

KCNQ1 opposite strand/antisense transcript 1

Gene

CYP1B1 antisense RNA 1

Gene

long intergenic non-protein coding RNA 3014

Gene

uncharacterized LOC729732

Gene

MIR124-1 host gene

Gene

POM121 membrane glycoprotein (rat) pseudogene

  • Gene

    long intergenic non-protein coding RNA 2910


  • Gene

    long intergenic non-protein coding RNA 2035


  • Gene

    TRG antisense RNA 1


  • Gene

    ITGB2 antisense RNA 1


  • Gene

    KCNQ1 opposite strand/antisense transcript 1


  • Gene

    CYP1B1 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 3014


  • Gene

    uncharacterized LOC729732



  • Gene

    POM121 membrane glycoprotein (rat) pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.